The following represents disclosure information provided by authors of this abstract. The program committee has reviewed all presenting author disclosure reports, identified potential conflicts of interest, and implemented strategies to manage those areas of conflict, where appropriate. All relationships are considered compensated. Relationships are self-held unless otherwise noted. I = Immediate Family Member, Inst = My Institution
 
Open Payments is a public database containing information reported by companies about payments made to US-licensed physicians (Open Payments)
Phase II study evaluating the efficacy of PDS0301 in combination with hepatic artery infusion pump (HAIP) and systemic therapy for patients with metastatic colorectal cancer or intrahepatic cholangiocarcinoma.
 
Jonathan Matthew Hernandez
No Relationships to Disclose
 
M. Cecilia Monge B.
No Relationships to Disclose
 
Jack Victory
No Relationships to Disclose
 
Cathleen Hannah
No Relationships to Disclose
 
Kathleen Smith
No Relationships to Disclose
 
Emily Smith
No Relationships to Disclose
 
Leila Sarvestani
No Relationships to Disclose
 
Tracey Pu
No Relationships to Disclose
 
Carolina Larrain
No Relationships to Disclose
 
Kenneth Luberice
No Relationships to Disclose
 
Lindsay Friedman
No Relationships to Disclose
 
Ashley Rainey
No Relationships to Disclose
 
Hannah Stepp
No Relationships to Disclose
 
Alyssa Eade
No Relationships to Disclose
 
Andrew M. Blakely
No Relationships to Disclose
 
Jeremy Davis
No Relationships to Disclose
 
Sofia Gameiro
No Relationships to Disclose
 
Jeffrey Schlom
Research Funding - Bavarian Nordic (Inst); EMD Serono/Merck (Inst); ImmunityBio (Inst); Incyte (Inst); NextCure (Inst); PDS Biotechnology (Inst); Pfizer (Inst); Precigen (Inst); Syndax (Inst); Syntrix Biosystems (Inst)
Patents, Royalties, Other Intellectual Property - If applicable; If applicable (Inst)
 
James L. Gulley
Research Funding - Astellas Medivation (Inst); Bavarian Nordic (Inst); Bristol-Myers Squibb (Inst); EMD Serono (Inst); ImmunityBio (Inst); Incyte (Inst); Janssen Oncology (Inst); Kite, a Gilead company (Inst); Marengo Therapeutics (Inst); Merck (Inst); NextCure (Inst); PDS Biotechnology (Inst); Pfizer (Inst); Precigen (Inst); Syndax (Inst); Syntrix Biosystems (Inst)
Patents, Royalties, Other Intellectual Property - COMBINATION PDL1 AND TGF-BETA BLOCKADE IN PATIENTS WITH HPV+ MALIGNANCIES Publication number: 20200062849 Abstract: The invention provides a method of inhibiting a malignancy associated with human papilloma virus (HPV) comprising administering to a subje
 
Tim F. Greten
No Relationships to Disclose